Another year has come and gone and we’re grateful that we continue to be able to develop new trials and work towards improving the lives of those affected by cancer. The challenges brought by the pandemic hasn’t stop us at all and in this new normal we’ve continued to adapt and strive for the best clinical trials in oncology. To all of you involved in this 2021, thank you.
Please join us to review an amazing year together:
January: Oncology Tube interviewed Dr. Antonio Llombart-Cussac on the BIOPER and PARSIFAL trials.
February: One of the most reputable online journals in Medical Oncology, Cancer Network, shared our new study, PHERGain-2, on its platform.
March: We expanded into another tumor type with the PECATI study that aims to evaluate the efficacy and safety of the combination of Pembrolizumab and Lenvatinib in patients with pre-treated metastatic thymic carcinoma or B3-thymoma.
April: The results of the KELLY trial, which showed a promising antitumoral activity of and acceptable safety profile of eribulin in combination with pembrolizumab for heavily pretreated, HR+/HER2– locally recurrent or MBC were published in the EJC.
May: Final results of our PHERGain trial, which was strategically-designed to gradually adapt treatment of each patient based on the therapeutic response observed to be performed on patients with localized HER2-positive breast cancer, were published in the Lancet.
June: The Spanish magazine “Saber Vivir” wrote about breast cancer with brain metastases in which they highlighted our two studies DEBBRAH and PHENOMENAL. Currently there is no authorized treatment focused on this type of metastasis.
July: Dr. Alfonso Gómez de Liaño, one of the PIs of our MEDSIR-sponsored ORPHEUS Trial, had a conversation with a Spanish local radio ECCA Radio about the importance of early detection in penile cancer. ORPHEUS is evaluating Retifanlimab for advanced penile squamous cell carcinoma.
August: We started a new clinical trial ABIGAIL that will compare the efficacy of abemaciclib in combination with endocrine therapy (letrozole or fulvestrant), with a short course of chemotherapy as first-line treatment in patients HR+/HER2- breast cancer, and is either locally advanced and inoperable or metastatic with aggressive disease criteria.
September: This year Dr. Vizcarra shared the results of our crowdfunded COPERNICO trial at European Respiratory Society 2021 Virtual Congress. The combination of tocilizumab plus pembrolizumab for COVID-19 pneumonia resulted in a hospitalization stay of only 10 days compared to 47 for standard of care.
October: The final results of the PARSIFAL study were published in JAMA Oncology, demonstrating that the combination of palbociclib plus fulvestrant had similar efficacy to the standard of care palbociclib plus letrozole, offering a wider therapeutic window for advanced-untreated breast cancer patients.
November: The results from the AZENT trial were published in the European Journal of Cancer. Designed and scientifically led by Dr. Rafael Rosell, this study investigated the efficacy and safety of first-line osimertinib in patients with EGFR-mutated advanced NSCLC harboring a coexisting low allelic fraction of EGFR Thr790Met mutation.
December: This year we were able to participate in person and present 5 sponsored studies presented at SABCS. Results from DxCARTES and LINGain were shared and we introduced the ongoing trials ABIGAIL and PHERGain-2. Preliminary results of DEBBRAH trial, were shared in the spotlight session “Brain Metastases: Managing leptomeningeal disease / targeting HER2” and created a lot of excitement for this trial!
AND WE'VE DONE SO MUCH MORE...
We began our international expansion
In efforts to become the global leader in clinical trial strategy and development, we expanded to the United States! And this is just the start! We keep generating ideas Our team was busy helping bring ideas to life this year. In 2021 we worked with 12 new idea generators and 1 new company. We developed 77 new ideas so far! New Trials and Continuing Trials In total there are 22 active clinical trials at MEDSIR. Also, this year we enrolled 431 new patients, opened 38 new sites, and are present in 4 new countries! We had a global presence at Conferences At MEDSIR we participated in 6 difference conferences with 11 different posters and presentations. This year we participated in IASLC, ESMO, ERS, SEOM, and SABCS. Publications We had 13 publications, 5 of which were related to our clinical trials. We are proud we've been published in The Lancet Oncology, the European Journal of Cancer, JAMA Oncology, and Clinical Lung Cancer! BIG Shoutout to Dr. Javier Cortés! We would like to again congratulate Dr. Javier Cortés for being awarded the European Award in Medicine for Medical Oncology. What an amazing accomplishment!